Response of brain metastases from breast cancer to megestrol acetate: A case report
A 56 year old women was treated with megestrol acetate (Megace) 40 mg p.o. q.i.d. for her cerebellar metastasis of primary adenocarcinoma of the breast. She had previously undergone two surgical resections of her brain metastasis, and a course of radiotherapy. After failing to tolerate tamoxifen therapy, she received Megace, with marked improvement in her cerebellar tumor on CT scans. Despite good control of her brain tumor with Megace, she developed progressive neurological symptoms thought to be due to meningeal carcinomatosis, and died two years after initiating Megace therapy. We conclude that Megace could potentially be beneficial in some patients with brain metastases from adenocarcinoma of the breast.
Key wordsmegace brain metastases breast cancer
Unable to display preview. Download preview PDF.
- 4.Stewart DJ: A critique of the role of the blood-brain barrier in the chemotherapy of human brain tumors. J Neuro-Oncol 20: 121–139, 1994Google Scholar
- 6.Hildebrand J, Brihaye J, Wagenknecht L, Michel J, Kenis Y: Combination chemotherapy with CCNU, vincristine and methotrexate in primary and metastatic brain tumors. Europ J Cancer 11: 585–587, 1975Google Scholar
- 8.Carey RW, Davis JM, Zervas NT: Tamoxifen-induced regression of cerebral metastases in breast carcinomas. Can Treat Rep 65: 793–795, 1981Google Scholar
- 9.Hansen SB, Galsgard H, von Eyben FE, Westergaard-Nielsen V, Wolf-Jensen J: Tamoxifen for brain metastases from breast cancer. Ann Neurol 20: 544, 1986Google Scholar
- 10.Pors H, von Eyben Fe, Sorensen OS, Larsen M: Longterm remission of multiple brain metastases with tamoxifen. J Neuro-Oncol 10: 173–177, 1991Google Scholar